TransMedics Group Inc TMDX

Morningstar Rating
$138.97 −4.83 (3.36%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TMDX is trading at a 642% premium.
Price
$143.52
Fair Value
$757.45
Uncertainty
High
1-Star Price
$939.95
5-Star Price
$135.62
Economic Moat
Jvngw
Capital Allocation

News

Trading Information

Previous Close Price
$143.80
Day Range
$137.74146.98
52-Week Range
$36.42177.37
Bid/Ask
$139.10 / $139.73
Market Cap
$4.63 Bil
Volume/Avg
1.2 Mil / 974,308

Key Statistics

Price/Earnings (Normalized)
3,459.98
Price/Sales
13.10
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Growth
Total Number of Employees
584

Comparables

Valuation

Metric
TMDX
BLFS
PLSE
Price/Earnings (Normalized)
3,459.98
Price/Book Value
24.383.5232.72
Price/Sales
13.109.11
Price/Cash Flow
64.59
Price/Earnings
TMDX
BLFS
PLSE

Financial Strength

Metric
TMDX
BLFS
PLSE
Quick Ratio
8.171.694.39
Current Ratio
9.372.864.57
Interest Coverage
−0.03−34.50
Quick Ratio
TMDX
BLFS
PLSE

Profitability

Metric
TMDX
BLFS
PLSE
Return on Assets (Normalized)
3.24%−3.37%−60.57%
Return on Equity (Normalized)
15.23%−4.08%−79.60%
Return on Invested Capital (Normalized)
3.23%−3.31%−69.89%
Return on Assets
TMDX
BLFS
PLSE

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
FhdjcpyzQvqsmj$196.0 Bil
Stryker Corp
SYK
QfrszdmbFtlk$133.8 Bil
Boston Scientific Corp
BSX
MpspwwxrCjmynd$124.5 Bil
Medtronic PLC
MDT
PpvlzztwNbdmtgv$113.2 Bil
Edwards Lifesciences Corp
EW
SkhxymyzFpskcb$39.5 Bil
Koninklijke Philips NV ADR
PHG
ThlqnHbjff$30.1 Bil
DexCom Inc
DXCM
XpvvwwkszgCfzk$27.3 Bil
Steris PLC
STE
MwyffjzbRdvyqp$22.8 Bil
Zimmer Biomet Holdings Inc
ZBH
CnvwxpkwbVmv$21.3 Bil
Insulet Corp
PODD
DbvmnjcxswJjqkh$16.1 Bil

Sponsor Center